Kong GA - Search Results

1

Drug targeting using thermally responsive polymers and local hyperthermia.

Meyer DE, Shin BC, Kong GA, Dewhirst MW, Chilkoti A. Meyer DE, et al. Among authors: kong ga. J Control Release. 2001 Jul 6;74(1-3):213-24. doi: 10.1016/s0168-3659(01)00319-4. J Control Release. 2001. PMID: 11489497

2

Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia.

Meyer DE, Kong GA, Dewhirst MW, Zalutsky MR, Chilkoti A. Meyer DE, et al. Among authors: kong ga. Cancer Res. 2001 Feb 15;61(4):1548-54. Cancer Res. 2001. PMID: 11245464

3

Hyperthermia and liposomes.

Kong G, Dewhirst MW. Kong G, et al. Int J Hyperthermia. 1999 Sep-Oct;15(5):345-70. doi: 10.1080/026567399285558. Int J Hyperthermia. 1999. PMID: 10519688 Free article. Review.

4

A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model.

Needham D, Anyarambhatla G, Kong G, Dewhirst MW. Needham D, et al. Cancer Res. 2000 Mar 1;60(5):1197-201. Cancer Res. 2000. PMID: 10728674

5

Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature.

Kong G, Braun RD, Dewhirst MW. Kong G, et al. Cancer Res. 2001 Apr 1;61(7):3027-32. Cancer Res. 2001. PMID: 11306483

6

Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size.

Kong G, Braun RD, Dewhirst MW. Kong G, et al. Cancer Res. 2000 Aug 15;60(16):4440-5. Cancer Res. 2000. PMID: 10969790

7

Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.

Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. Kong G, et al. Cancer Res. 2000 Dec 15;60(24):6950-7. Cancer Res. 2000. PMID: 11156395

8

Noninvasive visualization of tumors in rodent dorsal skin window chambers.

Huang Q, Shan S, Braun RD, Lanzen J, Anyrhambatla G, Kong G, Borelli M, Corry P, Dewhirst MW, Li CY. Huang Q, et al. Nat Biotechnol. 1999 Oct;17(10):1033-5. doi: 10.1038/13736. Nat Biotechnol. 1999. PMID: 10504711 No abstract available.

9

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Larkin J, et al. J Clin Oncol. 2018 Feb 1;36(4):383-390. doi: 10.1200/JCO.2016.71.8023. Epub 2017 Jul 3. J Clin Oncol. 2018. PMID: 28671856 Free PMC article. Clinical Trial.

10

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS. Weber JS, et al. Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Lancet Oncol. 2016. PMID: 27269740 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters